How Indianapolis Life Sciences Companies Are Growing Beyond Eli Lilly in 2026
The GLP-1 manufacturing boom drew the headlines. But a quieter expansion is reshaping where Indianapolis companies hire, build, and locate. Contract manufacturers, lab districts, institutional spin…
The GLP-1 manufacturing boom drew the headlines. But a quieter expansion is reshaping where Indianapolis companies hire, build, and locate. Contract manufacturers, lab districts, institutional spinoffs — these are the pieces that matter now.
When Eli Lilly announced its $9 billion–plus manufacturing campus outside Lebanon in Boone County, the local coverage was predictably Lilly-centric. Jobs. Tax abatements. Governor’s handshake photos. What received less attention was the radius effect — the concentric ring of contract manufacturers, cold-chain logistics operators, fill-finish specialists, and bioprocess suppliers that began making their own site decisions with Lilly’s Boone County plant as the fixed point on the map.
That secondary story is now the primary one.
In 2026, Indianapolis’s life sciences sector has moved far enough from its Lilly dependency that the question site selectors, real estate brokers, and workforce planners are actually asking isn’t whether Lilly will keep growing. It’s whether the network Lilly’s gravity has pulled into orbit can stand on its own — the CDMOs, the diagnostics giants, the 16 Tech tenants, the IBRI spinoffs. Early evidence suggests it’s trying harder than most outsiders realize, and succeeding in ways the city hasn’t fully learned to talk about yet. That gap between what’s actually being built here and the story we’re telling about it is something worth pressing on.
The Supply Chain That Lilly Built Without Meaning To
Lilly’s Boone County campus is a magnet with a commercial real estate consequence. A facility at that scale doesn’t just employ people inside its fence line. It generates demand for everything from specialized packaging and labeling to quality-control testing to temperature-controlled freight. You can see it in the lease activity.
Contract packaging and pharma-adjacent firms have leased space in the Anson development corridor, with proximity to Lilly’s Lebanon operations cited as a factor in area commercial real estate activity. Cold-chain specialists have expanded their Indianapolis-area warehouse footprint along I-65’s northern corridor to serve both Lilly’s supply chain and the broader pharma distribution market it has accelerated.
The Indiana Economic Development Corporation’s EDGE credit application records are public. If you want to understand which specific firms have cited Boone County proximity in their filings — who’s actually betting on this corridor — that’s where to look.
The economics are straightforward. A pharmaceutical manufacturer spending $9 billion on a single campus needs redundant local-supplier relationships across dozens of input categories: raw material handling, analytical services, sterilization, secondary packaging. Competitors based in Boston’s Kendall Square or Research Triangle Park can’t capture those relationships at competitive logistics costs. Indianapolis firms that understood this early planted flags in Boone County before lease rates there fully reflected the demand shift.
Land in the Whitestown/Zionsville belt along I-65 north of I-865 remains meaningfully cheaper per acre than comparable industrial-zoned parcels in Hamilton County’s Fishers or Carmel submarkets. Interstate access from the Lebanon facility to I-65 and I-74 is direct. For CDMOs and specialty logistics operators, those economics justify the geography — and then some.
Catalent, Elanco, and the Contract Pharma Question
The most consequential open question in Indianapolis life sciences doesn’t involve a startup. It involves what Novo Nordisk’s 2024 acquisition of Catalent means for the Indianapolis-area employees at Catalent’s facilities in the region.
Catalent has operated in this market for years, running fill-finish and drug delivery operations with a workforce that represents some of the more technically skilled manufacturing jobs in the city’s life sciences base. When Novo completed the acquisition, the stated rationale was securing additional GLP-1 manufacturing capacity — the same category of demand driving Lilly’s Lebanon buildout. For local retention advocates, that framing was largely reassuring: if Novo needs more capacity, Catalent’s existing facilities are an asset, not a liability.
The question worth watching is whether Novo integrates Catalent’s Indianapolis operations into its own manufacturing network on Novo’s terms, or maintains the CDMO operating model that made Catalent’s local presence valuable to a diverse client base. Those are genuinely different outcomes for the workers and for the cluster. A facility reoriented entirely toward Novo’s internal pipeline is a different employer than a CDMO serving dozens of clients. As of mid-2026, the company hasn’t announced Indianapolis headcount reductions, and local workforce planners have described the situation as stable. But nobody in the sector is calling it resolved. My read: the optimistic framing is plausible but not yet earned.
Elanco presents a different story. Eight years removed from its 2018 spinoff from Lilly, it has matured into a standalone global animal health company with its operational headquarters and significant R&D presence in Greenfield, Hancock County. The company runs its own research pipeline across parasiticides, vaccines, and therapeutics for both companion animals and livestock.
Elanco has had difficult financial years recently, but its Indiana footprint has remained largely intact. Its Greenfield campus continues to anchor Hancock County’s life sciences base east of Indianapolis. Other CDMOs with confirmed regional footprints serve both the human pharma and animal health segments — a diversity that builds cluster strength where it didn’t exist five years ago.
Roche, Zimmer Biomet, and the Stabilizing Middle Tier
If Lilly and the Catalent transition are the high-volatility end of the spectrum, Roche Diagnostics in Fishers and Zimmer Biomet’s Indianapolis presence occupy much steadier terrain. Less dramatic. Probably underappreciated in the innovation district conversations that dominate local coverage.
Roche Diagnostics has maintained major operations in Fishers for years and is one of the largest life sciences employers in the region outside Lilly itself. The company’s diagnostics portfolio has continued expanding with post-pandemic demand stabilization — point-of-care instruments, laboratory analyzers, molecular diagnostics. Roche has maintained its Fishers footprint through multiple rounds of global restructuring that trimmed headcount in other markets. When you look at what those restructuring cycles did elsewhere, that’s actually a remarkable retention story that Hamilton County doesn’t get enough credit for.
Zimmer Biomet, the orthopedic device maker headquartered in Warsaw, maintains a significant Indianapolis-area corporate and commercial presence even as its manufacturing is anchored further north. Its Indianapolis-area offices house commercial, regulatory, and business functions that connect directly to the city’s professional services ecosystem, which we track in our business and professional coverage.
This tier clusters most heavily along the Meridian corridor’s north end and throughout Hamilton County’s suburban belt from Carmel through Fishers. The footprint looks more like traditional corporate office and suburban flex space than the wet-lab buildouts at 16 Tech, which partly explains why it gets less attention. The optics aren’t as photogenic. The jobs are real.
These companies run ongoing hiring cycles across clinical affairs, quality assurance, regulatory submissions, and field sales that collectively represent a substantial number of open positions in any given year. If you’re a life sciences professional in this market and you’re not watching Roche’s Fishers listings, you’re leaving opportunities on the table.
Where the Companies Are Actually Landing
Indianapolis life sciences real estate has three distinct geographic expressions in 2026.
16 Tech occupies approximately 50 acres on the near-northwest side adjacent to IU Indianapolis’s campus and remains the city’s most concentrated address for early-stage life sciences tenants and research-adjacent companies. The 16 Tech Community Corporation tracks occupancy and pipeline figures; current vacancy and lease rates should be confirmed directly with the corporation or through CBRE Indianapolis and JLL Indianapolis market reports, as 2026 figures weren’t available at press time.
The spread between Indianapolis wet lab rates and those in established coastal markets continues to be a meaningful recruiting argument for companies trying to extend runway. Anyone who’s watched a promising local startup pack up for Cambridge because the rent math stopped working knows exactly why this matters. The district’s current tenant roster includes diagnostics startups, clinical research organizations, and medical device development companies alongside tenants serving IBRI’s research programs. Pipeline projects under development include additional lab-ready space designed for companies at the Series A and B stage that have outgrown incubator configurations but aren’t ready for standalone suburban campuses.
The Northwest Corridor — Boone County’s Whitestown, Zionsville, and Lebanon industrial submarkets — is the fastest-changing geography in regional life sciences real estate. Proximity to the Lilly Lebanon campus drives almost all of it. Industrial and flex-industrial lease rates remain below Hamilton County comparables, and the corridor’s I-65 access has attracted not just pharma-adjacent firms but also general bioprocessing supply companies serving the broader manufacturing cluster.
Drive it if you haven’t recently. New construction configured for pharmaceutical and cold-chain operations reflects demand created by the Lebanon campus’s buildout in ways that are striking if you remember what that stretch looked like five years ago.
The Hamilton County suburban belt spans Carmel, Fishers, and Westfield and remains the preferred address for established diagnostics, device, and specialty pharma companies. Roche’s Fishers operations anchor the cluster, but it includes dozens of smaller clinical and regulatory affairs firms, specialty CROs, and medical technology companies in suburban office and flex space. Lease rates are higher than the northwest corridor, but the payoff is proximity to one of the most education-dense suburban workforces in the Midwest — for context on what that office space premium actually looks like in dollar terms, downtown Indianapolis office costs offer a useful reference point. For a company trying to hire a regulatory affairs director or a clinical data manager, that workforce density is worth the premium.
IBRI’s Commercial Pipeline, and the Funding Question Nobody Is Asking
The Indiana Biosciences Research Institute, housed within 16 Tech and funded by a consortium of Indiana’s major research universities, the state, and the pharmaceutical industry, was founded on a model that remains unusual in American life sciences policy: a pre-competitive research organization designed from the start to generate commercial IP, not just publications.
IBRI operates through research programs focused on metabolic disease and diabetes, running studies partially funded by its pharma partners — Lilly among them — in exchange for rights to research outputs. The venture studio model built on top of that infrastructure is the intended commercial bridge. IBRI identifies research with startup potential, licenses IP to newly formed companies, and helps those companies raise outside capital. On paper, it’s a genuinely clever structure.
The scorecard on spinoff activity is mixed. IBRI has generated a small number of confirmed spinout companies since its founding, with early-stage capital raises that validate the model without yet producing the Series B and C deal flow that would mark Indianapolis as a competitive biotech formation market. That’s not a dismissal — the model is still relatively young, and early-stage commercialization timelines in life sciences are long. But the expectation gap is real, and local accounts that skip past it aren’t doing anyone favors.
What has received almost no public coverage is the funding cliff. IBRI was established on roughly ten-year financial commitments from its founding consortium members. As those commitments approach renewal, the question of whether Indiana’s pharma partners and state government will recommit at comparable levels — or restructure the model under fiscal pressure — is the single most consequential governance question in local life sciences policy.
IBRI leadership hasn’t signaled a crisis publicly. But the renewal timeline warrants scrutiny. Anyone planning a long-term relationship with the institute’s research programs should be asking about it directly. Don’t wait for a press release, because you probably won’t get one until decisions are already made.
Whether the Training Pipeline Is Scaled to the Moment
The workforce question for Indianapolis life sciences in 2026 isn’t whether talent exists. It’s whether the training infrastructure is producing enough of the right people fast enough.
Lilly’s Lebanon buildout, Catalent’s operations, the growing CDMO cluster — collectively, these represent a hiring surge that the existing training pipeline is struggling to match. That’s not a knock on the institutions. The demand materialized fast.
Ivy Tech Community College’s biomanufacturing program covers GMP manufacturing operations, bioprocess fundamentals, and quality systems training. The program has seen interest grow in ways that track employer signaling from the sector. Employer partnerships provide equipment, curriculum input, and co-op placements. It’s working — just not yet at scale.
Purdue Polytechnic Indianapolis runs bioprocess technician and laboratory science training at the associate and certificate level for students who want direct entry into manufacturing or QA roles rather than four-year research tracks. Its presence in the Indianapolis market creates a practical co-op and hiring pipeline that has attracted attention from both IBRI affiliates and diagnostics companies looking for lab support staff.
IU School of Medicine’s output in clinical research, regulatory affairs, and physician-scientist training feeds the higher-credential end of the sector. IU Health’s physical integration with the broader 16 Tech area makes the geography of that connection unusually direct — one of those structural advantages that’s easy to take for granted until you try to replicate it somewhere else.
The consistent assessment from life sciences hiring managers is that supply is improving but hasn’t caught up to demand. Biomanufacturing operators remain genuinely difficult to hire in volume. These are the people who run GMP production lines, document batch records, and troubleshoot equipment in regulated environments — unglamorous, highly skilled, essential work. The Ivy Tech and Purdue Polytechnic programs are producing the right credential. Enrollment capacity isn’t yet scaled to what the Lebanon corridor will ultimately require.
What’s Still Missing
Venture capital is the most persistent structural weakness, and it’s been that way long enough that describing it as “emerging” is no longer honest. Indianapolis has active early-stage investors who participate in seed and Series A deals. What it lacks is the density of Series B and C biotech investment that would allow locally formed companies to scale without relocating to Boston, San Diego, or the Bay Area.
Companies that spin out of IBRI or emerge from 16 Tech’s incubator routinely face a capital desert between their first institutional round and the scale round. Until that gap closes, Indianapolis will continue to be a good place to start a life sciences company and a hard place to grow one past early clinical stage. Local boosters who treat this as a temporary problem to be wished away aren’t helping anyone.
The Catalent situation remains unresolved in ways that matter. The Novo Nordisk acquisition could signal stability or create concentration risk, depending on integration decisions that haven’t been made public. That uncertainty is appropriate to name plainly.
The northwest corridor CDMO concentration is real, but its durability deserves honest scrutiny — not just in private conversations at IEDC events. If Lilly’s manufacturing priorities shift, the supply chain vendors that located in Boone County specifically to serve the Lebanon campus face direct demand risk. Real cluster formation requires multiple anchor tenants and cross-selling vendor relationships. The Lebanon corridor has one enormous anchor and a growing set of dependent suppliers. That is a sophisticated supply chain, but it isn’t yet a cluster in the multi-directional sense that Boston’s Route 128 or Raleigh’s Triangle represent. The difference matters, and this is a better time to say it out loud than after the fact.
IBRI’s funding continuity question deserves a specific answer before Indiana’s next legislative session. The institute is the most ambitious piece of the city’s life sciences infrastructure. It was built on time-limited commitments. Business and policy audiences should be asking consortium members and state officials directly: Are those commitments being renewed, at what level, and on what conditions?
None of this discounts what Indianapolis has built. A city that hosts a $9 billion–plus pharmaceutical manufacturing complex, a functioning innovation district with competitive wet lab capacity, established diagnostics and device employers in Hamilton County, a maturing CDMO community, and workforce pipelines at multiple educational levels has accomplished something most mid-sized American cities genuinely have not.
But the parts that don’t yet exist — primarily the venture capital infrastructure and a deeper IBRI commercialization track record — need to be built before the window created by Lilly’s gravity closes. The sector is moving on its own terms. Whether it has the depth to sustain that momentum is the question the next two years will answer.
CityDesk Indianapolis reporting notes: IBRI tenant roster and spinoff activity figures should be confirmed with IBRI communications directly. Lease rate data should be verified through CBRE Indianapolis and JLL Indianapolis Q1 2026 market reports before any figures are published. Catalent workforce status is based on most recent available public filings and local economic development communications. Roche Diagnostics Fishers headcount and Ivy Tech enrollment figures should be confirmed through IEDC records and direct institutional contact. Readers with updated figures or corrections are encouraged to contact the newsroom.
